Raymond James Trust’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $13.3M | Buy |
458,248
+16,827
| +4% | +$491K | 0.29% | 77 |
|
|
2024
Q2 | $12.4M | Sell |
441,421
-29
| -0% | -$798 | 0.29% | 76 |
|
|
2024
Q1 | $12.3M | Sell |
441,450
-85,852
| -16% | -$2.38M | 0.3% | 76 |
|
|
2023
Q4 | $15.2M | Buy |
527,302
+11,374
| +2% | +$344K | 0.4% | 59 |
|
|
2023
Q3 | $17.1M | Sell |
515,928
-694
| -0.1% | -$24.5K | 0.51% | 49 |
|
|
2023
Q2 | $18.9M | Buy |
516,622
+15,136
| +3% | +$589K | 0.55% | 43 |
|
|
2023
Q1 | $20.5M | Buy |
501,486
+2,416
| +0.5% | +$104K | 0.65% | 32 |
|
|
2022
Q4 | $25.6M | Buy |
499,070
+14,720
| +3% | +$706K | 0.86% | 22 |
|
|
2022
Q3 | $21.2M | Buy |
484,350
+11,699
| +2% | +$568K | 0.79% | 26 |
|
|
2022
Q2 | $24.8M | Sell |
472,651
-16,037
| -3% | -$817K | 0.89% | 22 |
|
|
2022
Q1 | $25.3M | Buy |
488,688
+9,394
| +2% | +$487K | 0.78% | 25 |
|
|
2021
Q4 | $28.3M | Sell |
479,294
-24,520
| -5% | -$1.21M | 0.84% | 23 |
|
|
2021
Q3 | $21.7M | Sell |
503,814
-7,413
| -1% | -$328K | 0.72% | 31 |
|
|
2021
Q2 | $20M | Sell |
511,227
-11,890
| -2% | -$462K | 0.67% | 35 |
|
|
2021
Q1 | $19M | Sell |
523,117
-16,455
| -3% | -$584K | 0.66% | 36 |
|
|
2020
Q4 | $19.9M | Sell |
539,572
-65,829
| -11% | -$2.41M | 0.76% | 29 |
|
|
2020
Q3 | $21.1M | Sell |
605,401
-16,328
| -3% | -$572K | 0.91% | 20 |
|
|
2020
Q2 | $19.3M | Buy |
621,729
+986
| +0.2% | +$33.5K | 0.93% | 18 |
|
|
2020
Q1 | $19.2M | Sell |
620,743
-879
| -0.1% | -$30K | 1.14% | 16 |
|
|
2019
Q4 | $23.1M | Buy |
621,622
+29,317
| +5% | +$1.04M | 1.1% | 17 |
|
|
2019
Q3 | $20.2M | Buy |
592,305
+70,074
| +13% | +$2.55M | 1.04% | 18 |
|
|
2019
Q2 | $21.5M | Buy |
522,231
+6,412
| +1% | +$255K | 1.18% | 14 |
|
|
2019
Q1 | $20.8M | Sell |
515,819
-14,146
| -3% | -$567K | 1.2% | 14 |
|
|
2018
Q4 | $21.9M | Sell |
529,965
-37,236
| -7% | -$1.55M | 1.41% | 8 |
|
|
2018
Q3 | $23.7M | Sell |
567,201
-6,259
| -1% | -$241K | 1.34% | 8 |
|
|
2018
Q2 | $19.7M | Buy |
573,460
+28,100
| +5% | +$960K | 1.2% | 12 |
|
|
2018
Q1 | $18.4M | Buy |
545,360
+3,216
| +0.6% | +$111K | 1.27% | 10 |
|
|
2017
Q4 | $18.6M | Buy |
542,144
+6,383
| +1% | +$218K | 1.25% | 12 |
|
|
2017
Q3 | $18.1M | Buy |
535,761
+20,606
| +4% | +$662K | 1.3% | 12 |
|
|
2017
Q2 | $16.4M | Buy |
515,155
+4,882
| +1% | +$154K | 1.23% | 14 |
|
|
2017
Q1 | $16.6M | Buy |
510,273
+254
| +0% | +$8.01K | 1.26% | 12 |
|
|
2016
Q4 | $15.7M | Buy |
510,019
+26,280
| +5% | +$802K | 1.25% | 12 |
|
|
2016
Q3 | $15.5M | Buy |
483,739
+15,373
| +3% | +$514K | 1.34% | 11 |
|
|
2016
Q2 | $15.6M | Buy |
468,366
+1,550
| +0.3% | +$49.5K | 1.38% | 11 |
|
|
2016
Q1 | $13.1M | Buy |
466,816
+1,656
| +0.4% | +$47.3K | 1.22% | 13 |
|
|
2015
Q4 | $14.2M | Buy |
465,160
+40,844
| +10% | +$1.28M | 1.31% | 11 |
|
|
2015
Q3 | $12.6M | Sell |
424,316
-2,867
| -0.7% | -$91.9K | 1.42% | 8 |
|
|
2015
Q2 | $13.6M | Sell |
427,183
-22,666
| -5% | -$739K | 1.44% | 8 |
|
|
2015
Q1 | $14.8M | Buy |
449,849
+15,078
| +3% | +$479K | 1.59% | 4 |
|
|
2014
Q4 | $12.8M | Buy |
434,771
+18,662
| +4% | +$535K | 1.38% | 7 |
|
|
2014
Q3 | $11.7M | Sell |
416,109
-260
| -0.1% | -$7.3K | 1.34% | 10 |
|
|
2014
Q2 | $11.7M | Buy |
416,369
+10,088
| +2% | +$288K | 1.34% | 10 |
|
|
2014
Q1 | $12.4M | Buy |
406,281
+6,392
| +2% | +$191K | 1.52% | 5 |
|
|
2013
Q4 | $11.6M | Buy |
399,889
+30,086
| +8% | +$876K | 1.53% | 6 |
|
|
2013
Q3 | $10.1M | Sell |
369,803
-429
| -0.1% | -$11.7K | 1.55% | 7 |
|
|
2013
Q2 | $9.84M | Buy |
+370,232
| New | +$10.2M | 1.61% | 6 |
|
Other funds holding PFE
Raymond James Trust's PFE Position: Q3 2024 in Review
Raymond James Trust increased its Pfizer (PFE) stake by 3.8% in Q3 2024, buying an estimated $491K and bringing the position to 458,248 shares worth $13.3M. The position accounts for 0.29% of the portfolio, ranked #77.
Raymond James Trust first reported a position in PFE in Q2 2013 and has held it in 46 quarters since. The position peaked at $28.3M in Q4 2021. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.
- Raymond James Trust held 458,248 shares of Pfizer worth $13.3M as of Q3 2024.
- Raymond James Trust bought 16,827 Pfizer shares in Q3 2024, an estimated $491K.
- Pfizer made up 0.29% of Raymond James Trust's portfolio in Q3 2024, its #77 holding.
- Raymond James Trust first reported a position in Pfizer in Q2 2013 and has held it in 46 quarters since.
- Raymond James Trust's Pfizer position peaked at $28.3M in Q4 2021.
- 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.
Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.